Log in

NASDAQ:TTPH - Tetraphase Pharmaceuticals Stock Price, Forecast & News

-0.04 (-1.76 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: $2.23
50-Day Range
MA: $3.29
52-Week Range
Now: $2.23
Volume86,960 shs
Average Volume51,423 shs
Market Capitalization$6.73 million
P/E RatioN/A
Dividend YieldN/A
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TTPH



Sales & Book Value

Annual Sales$18.90 million
Book Value$29.72 per share


Net Income$-72,160,000.00
Net Margins-804.43%


Market Cap$6.73 million
Next Earnings Date3/12/2020 (Estimated)

Receive TTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

When did Tetraphase Pharmaceuticals' stock split? How did Tetraphase Pharmaceuticals' stock split work?

Shares of Tetraphase Pharmaceuticals reverse split before market open on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 26th 2019. An investor that had 100 shares of Tetraphase Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) posted its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($6.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.27) by $0.27. The biopharmaceutical company earned $3.34 million during the quarter, compared to analysts' expectations of $1.55 million. Tetraphase Pharmaceuticals had a negative return on equity of 152.06% and a negative net margin of 804.43%. View Tetraphase Pharmaceuticals' Earnings History.

When is Tetraphase Pharmaceuticals' next earnings date?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Tetraphase Pharmaceuticals.

What price target have analysts set for TTPH?

8 Wall Street analysts have issued 1-year price objectives for Tetraphase Pharmaceuticals' shares. Their forecasts range from $28.00 to $80.00. On average, they anticipate Tetraphase Pharmaceuticals' stock price to reach $58.00 in the next year. This suggests a possible upside of 2,500.9% from the stock's current price. View Analyst Price Targets for Tetraphase Pharmaceuticals.

What is the consensus analysts' recommendation for Tetraphase Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tetraphase Pharmaceuticals.

What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?

Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (12/5/2019)
  • 2. HC Wainwright analysts commented, "We are reiterating our Hold rating on PCRX shares after the company reported 2Q19 Exparel sales which were in-line with consensus. Given 3Q tends to be a low Q/Q growth quarter due to seasonality, we think this sets up the need for a big 4Q19 Exparel sales number for the company to beat guidance and for shares to meaningfully outperform. Additionally, we would expect shares to be volatile around updates from competitors HRTX (Buy, $17.87) and DRRX (Adam Walsh, Hold, $1.43) which we expect in the coming months – with positive updates from one or both weighing on shares. Overall, we continue to remain on the sidelines as we think shares seem fairly valued at these levels and the potential for incoming competition in the next ~6-12 months poses a headwind, in our view. Key Points Exparel sales met 2Q19 expectations and FY19 Exparel sales guidance was reiterated." (8/11/2019)
  • 3. Needham & Company LLC analysts commented, "Tetraphase reported $0.3M in U.S. Xerava sales, below our $2.5M and consensus $2M ests. We remain concerned that the commercial opportunity for the drug may be modest. Tetraphase continues to evaluate next-generation IV Gram- negative antibiotic 1 bronchopulmonary disposition trial. We expect an update on development strategy later this yr. Acinetobacter is a potential target pathogen. Preclinical studies of tetracycline oncology derivative TP-2846 are ongoing. Mgmt plans to provide more clarity around strategy and development path once these studies are completed. Maintain HOLD. We believe the company is likely to continue to face challenges w/ Xerava launch. Nevertheless, we have a favorable view toward decision to leverage synthetic tetracycline platform to expand into oncology." (5/12/2019)

Has Tetraphase Pharmaceuticals been receiving favorable news coverage?

News headlines about TTPH stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tetraphase Pharmaceuticals earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Tetraphase Pharmaceuticals.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totalling 321,600 shares, an increase of 82.6% from the October 31st total of 176,100 shares. Based on an average trading volume of 86,500 shares, the short-interest ratio is currently 3.7 days. Currently, 10.8% of the shares of the stock are short sold. View Tetraphase Pharmaceuticals' Current Options Chain.

Who are some of Tetraphase Pharmaceuticals' key competitors?

What other stocks do shareholders of Tetraphase Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Bank of America (BAC), Opko Health (OPK), Verastem (VSTM), Rite Aid (RAD) and Progenics Pharmaceuticals (PGNX).

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:
  • Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 60)
  • Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 54)
  • Dr. Jacques Dumas, Chief Scientific Officer (Age 53)
  • Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 48)
  • Mr. Larry G. Edwards, Chief Operating Officer (Age 47)

How do I buy shares of Tetraphase Pharmaceuticals?

Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of TTPH stock can currently be purchased for approximately $2.23.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $6.73 million and generates $18.90 million in revenue each year. The biopharmaceutical company earns $-72,160,000.00 in net income (profit) each year or ($27.40) on an earnings per share basis. Tetraphase Pharmaceuticals employs 119 workers across the globe.View Additional Information About Tetraphase Pharmaceuticals.

What is Tetraphase Pharmaceuticals' official website?

The official website for Tetraphase Pharmaceuticals is http://www.tphase.com/.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL WAY, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]

MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  354 (Vote Outperform)
Underperform Votes:  337 (Vote Underperform)
Total Votes:  691
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel